Breast Cancer Research and Treatment · 2019 · 42 citations · 46 references
MedicineOncologyPharmacologyBreast OncologyCancer PharmacologyMolecular OncologyBreast Cancer PharmacotherapyCancer Cell SignalingCell Cycle PharmacologyHormonal Cancer TherapyOncogenic Signaling PathwaysAurora Kinase FunctionAurora Kinase InhibitionBreast Cancer Resistance MechanismsCell Cycle InhibitionCell Division ControlMalignant Breast TumorsMap KinasesProtein Kinase Inhibitors
PURPOSE: The serine-threonine kinases Aurora A (AURKA) and p21-activated kinase 1 (PAK1) are frequently overexpressed in breast tumors, with overexpression promoting aggressive breast cancer phenotypes and poor clinical outcomes. Besides the well-defined roles of these proteins in control of cell division, proliferation, and invasion, both kinases support MAPK kinase pathway activation and can contribute to endocrine resistance by phosphorylating estrogen receptor alpha (ERα). PAK1 directly phosphorylates AURKA and its functional partners, suggesting potential value of inhibiting both kinases activity in tumors overexpressing PAK1 and/or AURKA. Here, for the first time, we evaluated the effect of combining the AURKA inhibitor alisertib and the PAK inhibitor FRAX1036 in preclinical models of breast cancer. METHODS: Combination of alisertib and FRAX1036 was evaluated in a panel of 13 human breast tumor cell lines and BT474 xenograft model, with assessment of the cell cycle by FACS, and signaling changes by immunohistochemistry and Western blot. Additionally, we performed in silico analysis to identify markers of response to alisertib and FRAX1036. RESULTS: Pharmacological inhibition of AURKA and PAK1 synergistically decreased survival of multiple tumor cell lines, showing particular effectiveness in luminal and HER2-enriched models, and inhibited growth and ERα-driven signaling in a BT474 xenograft model. In silico analysis suggested cell lines with dependence on AURKA are most likely to be sensitive to PAK1 inhibition. CONCLUSION: Dual targeting of AURKA and PAK1 may be a promising therapeutic strategy for treatment of breast cancer, with a particular effectiveness in luminal and HER2-enriched tumor subtypes.
46
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina, Giordano Caponigro, Nicolas Stransky et al. · Nature · 2012 · 8.5K citations
Medicine, Oncology, Pharmacology +15
A comprehensive transcriptional portrait of human cancer cell lines
Christiaan Klijn, Steffen Durinck, Eric Stawiski et al. · Nature Biotechnology · 2014 · 724 citations
Evolutionary dynamics of cancer in response to targeted combination therapy
Ivana Božić, Johannes G. Reiter, Benjamin Allen et al. · eLife · 2013 · 647 citations · Full text
Medicine, Cancer Biology, Oncology +14